In the second quarter, Johnson & Johnson reported a revenue increase of 6.6% year over year, totaling $25.31 billion, surpassing the LSEG consensus of $25.05 billion. Adjusted earnings per share reached $2.90, exceeding the $2.85 estimate.
Despite this positive performance, J&J's shares fell over 2% in afternoon trading, reflecting a historical trend where the stock typically does not react significantly to earnings announcements. Analysts believe that the company's consistent execution and robust pipeline, including the recently approved oral IL-23 inhibitor Icotyde, will drive future growth.
The pharmaceutical segment showed strong growth, particularly in cancer therapies, while the medical device division faced challenges, particularly in the cardiovascular unit, where sales fell short of expectations. However, overall MedTech sales grew, and management remains optimistic about addressing the issues in the cardiovascular segment.
The company is on track to achieve over $100 billion in sales for the first time this year, reinforcing confidence in its long-term prospects. CFO Joe Wolk acknowledged the underperformance in the cardiovascular unit but emphasized the company's broader strengths and commitment to improvement.
Investors are encouraged by the growth potential in J&J's drug portfolio, particularly with Icotyde and Tremfya, which are expected to contribute significantly to future revenues